Practical asymmetric synthesis of Efavirenz (DMP 266), an HIV-1 reverse transcriptase inhibitor

  • Michael E. Pierce
  • , Rodney L. Parsons
  • , Lilian A. Radesca
  • , Young S. Lo
  • , Stuart Silverman
  • , James R. Moore
  • , Qamrul Islam
  • , Anusuya Choudhury
  • , Joseph M.D. Fortunak
  • , Dieu Nguyen
  • , Chi Luo
  • , Susan J. Morgan
  • , Wayne P. Davis
  • , Pat N. Confalone
  • , Cheng Yi Chen
  • , Richard D. Tillyer
  • , Lisa Frey
  • , Lushi Tan
  • , Feng Xu
  • , Dalian Zhao
  • Andrew S. Thompson, Edward G. Corley, Edward J.J. Grabowski, Robert Reamer, Paul J. Reider

Research output: Contribution to journalArticlepeer-review

235 Scopus citations

Abstract

A highly enantioselective and practical synthesis of the HIV-1 reverse transcriptase inhibitor efavirenz (1) is described. The synthesis proceeds in 62% overall yield in seven steps from 4-chloroaniline (6) to give efavirenz (1) in excellent chemical and optical purity. A novel, enantioselective addition of Li-cyclopropyl acetylide (4a) to p-methoxybenzyl-protected ketoaniline 3a mediated by (1R,2S)-N-pyrrolidinylnorephedrine lithium alkoxide (5a) establishes the stereogenic center in the target with a remarkable level of stereocontrol.

Original languageEnglish (US)
Pages (from-to)8536-8543
Number of pages8
JournalJournal of Organic Chemistry
Volume63
Issue number23
DOIs
StatePublished - Nov 13 1998
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Practical asymmetric synthesis of Efavirenz (DMP 266), an HIV-1 reverse transcriptase inhibitor'. Together they form a unique fingerprint.

Cite this